Navigation Links
Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
Date:10/8/2008

PT. RICHMOND, Calif., Oct. 8 /PRNewswire/ -- Transcept Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, announced today that Thomas P. Soloway, Senior Vice President and Chief Financial Officer, is scheduled to present at the Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City on Monday, October 13, 2008 at 9:30 AM Eastern Time.

An audio webcast of the presentation will be available at http://www.wsw.com/webcast/nblr2/transcept/ and on the Transcept website at http://www.transcept.com. The replay of the presentation will be available for 30 days.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the fields of psychiatry and sleep medicine. The lead Transcept product candidate, Intermezzo(R), is a sublingual low dose formulation of zolpidem that has been developed for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep. Phase 3 clinical trials have been completed for Intermezzo(R) and, on September 30, 2008, Transcept submitted a New Drug Application to the U.S. Food and Drug Administration. For further information, please visit the company's website at: http://www.transcept.com.

Safe Harbor

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Transcept disclaims any intent or obligation to update these forward-looking statements, and claim the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the expected benefits of Transcept product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, Transcept product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA approval; physician or patient reluctance to use Intermezzo(R), if approved; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in, clinical development, obtaining regulatory approval, market acceptance and commercialization of Transcept product candidates.

Transcept Pharmaceuticals, Inc.

Michael Gill

Director of Communications

(510) 215-3575

mgill@transcept.com

The Ruth Group

Investors / Media

Stephanie Carrington / Jason Rando

(646) 536-7017 / 7025

scarrington@theruthgroup.com

jrando@theruthgroup.com


'/>"/>
SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Transcept Pharmaceuticals Appoints Key Senior Executives
2. Transcept Pharmaceuticals to Participate in Middle-of-the-Night (MOTN) Insomnia Investor Panel
3. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
4. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
5. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
7. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
8. VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC
9. Pacira Pharmaceuticals, Inc. Adds Board Member and Key Senior Management
10. Alseres Pharmaceuticals, Inc. Raises $5 Million
11. Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... ... the full spectrum of drug and device development, and Prism Clinical Research ... and clinicians, today announced Verified Clinical Trials (VCT) has been selected ...
(Date:1/19/2017)... Jan. 18, 2017 Acupath Laboratories, Inc., a ... formation of an Executive Committee that will guide the ... John Cucci , a 15-year veteran of ... of Business Development to Chief Sales Officer .  ... served in senior sales leadership roles at several leading ...
(Date:1/18/2017)... According to a new market research report "In situ ... & End User (Molecular Diagnostic Laboratories, Academic and Research Institutions) - Global Forecast ... Million by 2021 from USD 557.1 Million in 2016, growing at a CAGR ... ... MarketsandMarkets Logo ...
(Date:1/18/2017)... , Jan. 18, 2017   Parent Project Muscular ... to end Duchenne muscular dystrophy (Duchenne) , today ... New Jersey Institute of Technology (NJIT) and Talem Technologies ... of robotic technology to assist people living with ... NJIT,s technology – an embedded computer, software, a force ...
Breaking Biology Technology:
(Date:12/20/2016)... 2016   Valencell , the leading innovator ... STMicroelectronics (NYSE: STM), a global semiconductor leader serving ... today the launch of a new, highly accurate ... includes ST,s compact SensorTile turnkey multi-sensor ... sensor system. Together, SensorTile and Benchmark deliver the ...
(Date:12/16/2016)... 2016 Research and Markets has announced the ... Forecast to 2021" report to their offering. ... The biometric vehicle access system ... CAGR of 14.06% from 2016 to 2021. The market is estimated ... reach 854.8 Million by 2021. The growth of the biometric vehicle ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, Inc. ... genomics technology company, announced today that on December 13, ... Department of The Nasdaq Stock Market LLC which acknowledged ... price of WaferGen,s common stock had been at $1.00 ... has regained compliance with Listing Rule 5550(a)(2) of the ...
Breaking Biology News(10 mins):